Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E-β-thalassemia): a single center study from eastern India. (avab uue akna)

Bohara VV, Ray S, Chakrabarti P, Ray SS, Nath UK, Chaudhuri U.

Allikas‎: Hemoglobin 2014;38(1):44-8.

Indekseeritud‎: PubMed 24144212

DOI‎: 10.3109/03630269.2013.845844

https://www.ncbi.nlm.nih.gov/pubmed/24144212 (avab uue akna)

Hydroxyurea in thalassemia intermedia--a promising therapy. (avab uue akna)

Dixit A, Chatterjee TC, Mishra P, Choudhry DR, Mahapatra M, Tyagi S, Kabra M, Saxena R, Choudhry VP.

Allikas‎: Ann Hematol 2005;84(7):441-6.

Indekseeritud‎: PubMed 15838670

DOI‎: 10.1007/s00277-005-1026-4

https://www.ncbi.nlm.nih.gov/pubmed/15838670 (avab uue akna)

Effect of hydroxyurea on the transfusion requirements in patients with severe HbE-beta-thalassaemia: a genotypic and phenotypic study. (avab uue akna)

Italia KY, Jijina FF, Merchant R, Panjwani S, Nadkarni AH, Sawant PM, Nair SB, Ghosh K, Colah RB.

Allikas‎: J Clin Pathol 2010;63(2):147-50.

Indekseeritud‎: PubMed 20154037

DOI‎: 10.1136/jcp.2009.070391

https://www.ncbi.nlm.nih.gov/pubmed/20154037 (avab uue akna)

Echocardiographic finding in beta-thalassemia intermedia and major: absence of pulmonary hypertension following hydroxyurea treatment in beta-thalassemia intermedia. (avab uue akna)

Karimi M, Borzouee M, Mehrabani A, Cohan N.

Allikas‎: Eur J Haematol 2009;82(3):213-8.

Indekseeritud‎: PubMed 19077048

DOI‎: 10.1111/j.1600-0609.2008.01192.x

https://www.ncbi.nlm.nih.gov/pubmed/19077048 (avab uue akna)

Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. (avab uue akna)

Karimi M, Mohammadi F, Behmanesh F, Samani SM, Borzouee M, Amoozgar H, Haghpanah S.

Allikas‎: Eur J Haematol 2010;84(1):52-8.

Indekseeritud‎: PubMed 19799627

DOI‎: 10.1111/j.1600-0609.2009.01356.x

https://www.ncbi.nlm.nih.gov/pubmed/19799627 (avab uue akna)

Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece. (avab uue akna)

Loukopoulos D, Voskaridou E, Kalotychou V, Schina M, Loutradi A, Theodoropoulos I.

Allikas‎: Blood Cells Mol Dis 2000;26(5):453-66.

Indekseeritud‎: PubMed 11112383

DOI‎: 10.1006/bcmd.2000.0328

https://www.ncbi.nlm.nih.gov/pubmed/11112383 (avab uue akna)

Fetal globin stimulant therapies in the beta-hemoglobinopathies: principles and current potential. (avab uue akna)

Perrine SP.

Allikas‎: Pediatr Ann 2008;37(5):339-46.

Indekseeritud‎: PubMed 18543545

https://www.ncbi.nlm.nih.gov/pubmed/18543545 (avab uue akna)

Single and combination drug therapy for fetal hemoglobin augmentation in hemoglobin E-beta 0-thalassemia: Considerations for treatment. (avab uue akna)

Singer ST, Kuypers FA, Olivieri NF, Weatherall DJ, Mignacca R, Coates TD, Davies S, Sweeters N, Vichinsky EP.

Allikas‎: Ann N Y Acad Sci 2005;1054:250-6.

Indekseeritud‎: PubMed 16339672

DOI‎: 10.1196/annals.1345.031

https://www.ncbi.nlm.nih.gov/pubmed/16339672 (avab uue akna)

Treatment of beta-thalassemia patients with recombinant human erythropoietin: effect on transfusion requirements and soluble adhesion molecules. (avab uue akna)

Chaidos A, Makis A, Hatzimichael E, Tsiara S, Gouva M, Tzouvara E, Bourantas KL.

Allikas‎: Acta Haematol 2004;111(4):189-95.

Indekseeritud‎: PubMed 15153710

DOI‎: 10.1159/000077551

https://www.ncbi.nlm.nih.gov/pubmed/15153710 (avab uue akna)

Efficacy of erythropoietin on dialysis in patients with beta thalassemia minor. (avab uue akna)

Di Iorio B, De Nicola L, Bellizzi V, Minutolo R, Zamboli P, Rubino R, Fuiano G, Conte G.

Allikas‎: Blood Purif 2004;22(5):453-60.

Indekseeritud‎: PubMed 15359104

DOI‎: 10.1159/000080729

https://www.ncbi.nlm.nih.gov/pubmed/15359104 (avab uue akna)

The role of recombinant human erythropoietin in the treatment of thalassemia. (avab uue akna)

Rachmilewitz EA, Aker M.

Allikas‎: Ann N Y Acad Sci 1998;850:129-38.

Indekseeritud‎: PubMed 9668535

https://www.ncbi.nlm.nih.gov/pubmed/9668535 (avab uue akna)

Darbepoetin alfa for the treatment of anaemia in alpha- or beta- thalassaemia intermedia syndromes. (avab uue akna)

Singer ST, Vichinsky EP, Sweeters N, Rachmilewitz E.

Allikas‎: Br J Haematol 2011;154(2):281-4.

Indekseeritud‎: PubMed 21496003

DOI‎: 10.1111/j.1365-2141.2011.08617.x

https://www.ncbi.nlm.nih.gov/pubmed/21496003 (avab uue akna)

The emerging role of fetal hemoglobin induction in non-transfusion-dependent thalassemia. (avab uue akna)

Thein SL.

Allikas‎: Blood Rev 2012;26 Suppl 1:S35-9.

Indekseeritud‎: PubMed 22631042

DOI‎: 10.1016/S0268-960X(12)70011-5

https://www.ncbi.nlm.nih.gov/pubmed/22631042 (avab uue akna)